Hidroclorotiazida Aurovitas (Hydrochlorothiazide)

Hidroclorotiazida Aurovitas is indicated for conditions where reduction of excess fluid or lowering of blood pressure is required.

• Management of primary hypertension, either alone or as part of combination therapy with ACE inhibitors, ARBs, or beta‑blockers.
• Treatment of peripheral edema related to congestive heart failure, helping to relieve swelling in the lower extremities.
• Reduction of fluid accumulation in patients with hepatic cirrhosis, particularly those with ascites.
• Control of edema associated with chronic renal disease or nephrotic syndrome, aiding in the management of protein‑loss‑related swelling.
• Adjunctive therapy to facilitate diuresis in patients receiving other antihypertensive agents, improving overall blood‑pressure control.

• Hydrochlorothiazide acts on the distal convoluted tubule of the nephron by inhibiting the sodium‑chloride symporter (NCC). This blockade reduces reabsorption of Na⁺ and Cl⁻, leading to increased excretion of sodium, chloride, and accompanying water. The resulting mild volume depletion decreases cardiac output and peripheral vascular resistance, contributing to its antihypertensive effect. The drug also promotes calcium reabsorption, which can be beneficial in certain stone‑prevention strategies.

Like other thiazide diuretics, Hidroclorotiazida Aurovitas may cause adverse reactions, most of which are mild and reversible.

Common

• Increased frequency of urination accompanied by mild thirst, especially during the first weeks of therapy.
• Electrolyte disturbances such as reduced potassium (hypokalemia) or sodium (hyponatremia) that may cause muscle cramps or weakness.
• Dizziness or light‑headedness, particularly upon standing, due to transient volume depletion.
• Elevated blood glucose levels or mild hyperglycemia, which may be more noticeable in patients with diabetes.
• Headache or mild visual disturbances, often resolving with continued treatment.
• Nausea, vomiting, or abdominal discomfort that are usually transient.

Serious

• Severe electrolyte imbalance, such as marked hyponatremia or hypokalemia, which can precipitate cardiac arrhythmias or neuromuscular dysfunction.
• Acute gout attacks triggered by increased serum uric acid concentrations, presenting with painful joint inflammation.
• Allergic reactions ranging from maculopapular rash and pruritus to potentially life‑threatening angioedema or anaphylaxis.

Before initiating Hidroclorotiazida Aurovitas, clinicians should evaluate patient history and monitor specific clinical parameters to minimize risk.

• Assess baseline electrolyte levels, renal function, and blood pressure.
• Use caution in patients with a history of gout or hyperuricemia.
• Monitor blood glucose in diabetic patients, as thiazides may raise glucose levels.
• Avoid abrupt discontinuation, which can lead to fluid retention and blood‑pressure rebound.
• Evaluate for potential hypersensitivity, especially in individuals with known sulfonamide allergy.
• Adjust dose or discontinue in cases of severe renal impairment or hepatic dysfunction.

Hidroclorotiazida Aurovitas can affect the pharmacokinetics or pharmacodynamics of several medicines; awareness of these interactions helps maintain therapeutic effectiveness and safety.

Avoid

• Concurrent use with other potent diuretics (e.g., loop diuretics) that may cause excessive volume depletion.
• Combination with lithium, as thiazides can increase lithium concentrations and risk of toxicity.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) which may blunt the diuretic effect and impair renal function.
• ACE inhibitors, ARBs, or beta‑blockers, where additive blood‑pressure lowering may require dose adjustments.
• Antidiabetic agents, because thiazides can elevate blood glucose and may necessitate closer glucose monitoring.